Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors

Autor:	E. Fontana, A. Williams, G. Falchook, N. Lakhani, T.R.J. Evans, V. Gondi, F. Iwamoto, M. McKean, S. Symeonides, N. Butowski, A. McLaren, J. Henry, R. Buerki, J. Rotolo, G. Capiaux, R. Michel, S. Kaesshaefer, E. Wiegert, A. Bexon
Rok vydání:	2022
Předmět:	Cancer Research Oncology
Zdroj:	European Journal of Cancer. 174:S82-S83
ISSN:	0959-8049
DOI:	10.1016/s0959-8049(22)01018-8
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::15d6575b9e13e8c8f841cc16ff92e868 https://doi.org/10.1016/s0959-8049(22)01018-8 Zobrazit plný text záznamu Full Text from ScienceDirect